Infectious Disease Clinical Trials Update: Week 17, 2026

Published April 24, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Randomised Evaluation of COVID-19 Therapy

This large Phase 3 trial led by the University of Oxford is testing several treatments for patients hospitalized with pneumonia caused by COVID-19 and other infections. It aims to find therapies that can lower the risk of death and help patients recover faster. The study is taking place in 16 countries and includes a wide variety of patients, which could make the results applicable to many people worldwide.

Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults

This Phase 3 study from Novavax evaluated the safety and immune response of three different batches of their COVID-19 vaccine in adults aged 18 to 49. About 900 previously vaccinated adults in the United States participated. The results, now available, may help ensure consistent vaccine quality and support ongoing protection against COVID-19 for younger adults.

Outpatient Treatment With Anti-Coronavirus Immunoglobulin

The University of Minnesota is conducting a Phase 3 trial to test an intravenous immunoglobulin treatment for adults who have recently been diagnosed with COVID-19. This treatment aims to reduce how severe the illness becomes and help patients recover without needing to go to the hospital. The study is recruiting participants internationally, offering hope for an additional option to manage early-stage COVID-19.

Nitazoxanide for Treatment of Cryptosporidium in Children

This upcoming Phase 3 trial from Johns Hopkins Bloomberg School of Public Health will study nitazoxanide as a treatment for Cryptosporidium infection in children aged 6 to 12 months. If successful, the medication could shorten the duration of diarrhea and clear the parasite faster, improving health outcomes for young children. The study will involve a short, 3-day medication course and careful monitoring.

An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

GlaxoSmithKline is running a Phase 3b study testing a vaccine against Respiratory Syncytial Virus (RSV) in adults 60 years and older. This study looks at the best timing for revaccination and how long protection lasts. With over 10,000 participants across multiple countries, the research could lead to better prevention methods for older adults who are vulnerable to RSV infections.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.